vs
Avantor, Inc.（AVTR）与FIRST HORIZON CORP（FHN）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是FIRST HORIZON CORP的1.9倍（$1.7B vs $888.0M），FIRST HORIZON CORP净利率更高（29.4% vs 3.1%，领先26.2%），FIRST HORIZON CORP同比增速更快（21.8% vs -1.4%），FIRST HORIZON CORP自由现金流更多（$389.0M vs $117.2M），过去两年FIRST HORIZON CORP的营收复合增速更高（20.0% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
第一地平线公司（前身为第一田纳西银行）是一家成立于1864年的金融服务企业，总部位于美国田纳西州孟菲斯市。该公司通过旗下子公司第一地平线银行开展业务，网点覆盖美国东南部12个州，是该区域第四大区域性银行。
AVTR vs FHN — 直观对比
营收规模更大
AVTR
是对方的1.9倍
$888.0M
营收增速更快
FHN
高出23.2%
-1.4%
净利率更高
FHN
高出26.2%
3.1%
自由现金流更多
FHN
多$271.8M
$117.2M
两年增速更快
FHN
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $888.0M |
| 净利润 | $52.4M | $261.0M |
| 毛利率 | 31.5% | — |
| 营业利润率 | 7.6% | 38.5% |
| 净利率 | 3.1% | 29.4% |
| 营收同比 | -1.4% | 21.8% |
| 净利润同比 | -89.5% | 57.2% |
| 每股收益（稀释后） | $0.08 | $0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRFHN
| Q4 25 | $1.7B | $888.0M | ||
| Q3 25 | $1.6B | $889.0M | ||
| Q2 25 | $1.7B | $830.0M | ||
| Q1 25 | $1.6B | $812.0M | ||
| Q4 24 | $1.7B | $729.0M | ||
| Q3 24 | $1.7B | $827.0M | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | $819.0M |
净利润AVTRFHN
| Q4 25 | $52.4M | $261.0M | ||
| Q3 25 | $-711.8M | $262.0M | ||
| Q2 25 | $64.7M | $241.0M | ||
| Q1 25 | $64.5M | $218.0M | ||
| Q4 24 | $500.4M | $166.0M | ||
| Q3 24 | $57.8M | $218.0M | ||
| Q2 24 | $92.9M | — | ||
| Q1 24 | $60.4M | $192.0M |
毛利率AVTRFHN
| Q4 25 | 31.5% | — | ||
| Q3 25 | 32.4% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 33.8% | — | ||
| Q4 24 | 33.4% | — | ||
| Q3 24 | 32.9% | — | ||
| Q2 24 | 34.1% | — | ||
| Q1 24 | 34.0% | — |
营业利润率AVTRFHN
| Q4 25 | 7.6% | 38.5% | ||
| Q3 25 | -40.0% | 38.7% | ||
| Q2 25 | 7.7% | 37.2% | ||
| Q1 25 | 9.3% | 35.1% | ||
| Q4 24 | 37.8% | 28.8% | ||
| Q3 24 | 7.3% | 34.0% | ||
| Q2 24 | 10.3% | — | ||
| Q1 24 | 8.7% | 31.0% |
净利率AVTRFHN
| Q4 25 | 3.1% | 29.4% | ||
| Q3 25 | -43.8% | 29.5% | ||
| Q2 25 | 3.8% | 29.0% | ||
| Q1 25 | 4.1% | 26.8% | ||
| Q4 24 | 29.7% | 22.8% | ||
| Q3 24 | 3.4% | 26.4% | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 3.6% | 23.4% |
每股收益（稀释后）AVTRFHN
| Q4 25 | $0.08 | $0.51 | ||
| Q3 25 | $-1.04 | $0.50 | ||
| Q2 25 | $0.09 | $0.45 | ||
| Q1 25 | $0.09 | $0.41 | ||
| Q4 24 | $0.73 | $0.29 | ||
| Q3 24 | $0.08 | $0.40 | ||
| Q2 24 | $0.14 | — | ||
| Q1 24 | $0.09 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | — |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | $8.8B |
| 总资产 | $11.8B | $83.9B |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTRFHN
| Q4 25 | $365.4M | — | ||
| Q3 25 | $251.9M | — | ||
| Q2 25 | $449.4M | — | ||
| Q1 25 | $315.7M | — | ||
| Q4 24 | $261.9M | — | ||
| Q3 24 | $285.3M | — | ||
| Q2 24 | $272.6M | — | ||
| Q1 24 | $234.9M | — |
总债务AVTRFHN
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTRFHN
| Q4 25 | $5.6B | $8.8B | ||
| Q3 25 | $5.6B | $8.9B | ||
| Q2 25 | $6.3B | $9.0B | ||
| Q1 25 | $6.1B | $8.7B | ||
| Q4 24 | $6.0B | $8.8B | ||
| Q3 24 | $5.6B | $9.0B | ||
| Q2 24 | $5.4B | — | ||
| Q1 24 | $5.3B | $8.9B |
总资产AVTRFHN
| Q4 25 | $11.8B | $83.9B | ||
| Q3 25 | $11.7B | $83.2B | ||
| Q2 25 | $12.8B | $82.1B | ||
| Q1 25 | $12.3B | $81.5B | ||
| Q4 24 | $12.1B | $82.2B | ||
| Q3 24 | $12.8B | $82.6B | ||
| Q2 24 | $12.7B | — | ||
| Q1 24 | $12.8B | $81.8B |
负债/权益比AVTRFHN
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $396.0M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $389.0M |
| 自由现金流率自由现金流/营收 | 7.0% | 43.8% |
| 资本支出强度资本支出/营收 | 2.1% | 0.8% |
| 现金转化率经营现金流/净利润 | 2.91× | 1.52× |
| 过去12个月自由现金流最近4个季度 | $495.0M | $595.0M |
8季度趋势，按日历期对齐
经营现金流AVTRFHN
| Q4 25 | $152.7M | $396.0M | ||
| Q3 25 | $207.4M | $-200.0M | ||
| Q2 25 | $154.4M | $83.0M | ||
| Q1 25 | $109.3M | $349.0M | ||
| Q4 24 | $173.3M | $191.0M | ||
| Q3 24 | $244.8M | $389.0M | ||
| Q2 24 | $281.1M | — | ||
| Q1 24 | $141.6M | $838.0M |
自由现金流AVTRFHN
| Q4 25 | $117.2M | $389.0M | ||
| Q3 25 | $171.7M | $-208.0M | ||
| Q2 25 | $124.8M | $74.0M | ||
| Q1 25 | $81.3M | $340.0M | ||
| Q4 24 | $145.8M | $174.0M | ||
| Q3 24 | $204.0M | $383.0M | ||
| Q2 24 | $235.3M | — | ||
| Q1 24 | $106.9M | $828.0M |
自由现金流率AVTRFHN
| Q4 25 | 7.0% | 43.8% | ||
| Q3 25 | 10.6% | -23.4% | ||
| Q2 25 | 7.4% | 8.9% | ||
| Q1 25 | 5.1% | 41.9% | ||
| Q4 24 | 8.6% | 23.9% | ||
| Q3 24 | 11.9% | 46.3% | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 6.4% | 101.1% |
资本支出强度AVTRFHN
| Q4 25 | 2.1% | 0.8% | ||
| Q3 25 | 2.2% | 0.9% | ||
| Q2 25 | 1.8% | 1.1% | ||
| Q1 25 | 1.8% | 1.1% | ||
| Q4 24 | 1.6% | 2.3% | ||
| Q3 24 | 2.4% | 0.7% | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.1% | 1.2% |
现金转化率AVTRFHN
| Q4 25 | 2.91× | 1.52× | ||
| Q3 25 | — | -0.76× | ||
| Q2 25 | 2.39× | 0.34× | ||
| Q1 25 | 1.69× | 1.60× | ||
| Q4 24 | 0.35× | 1.15× | ||
| Q3 24 | 4.24× | 1.78× | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | 4.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
FHN
| Commercial Consumer And Wealth Segment | $776.0M | 87% |
| Other | $88.0M | 10% |
| Corporate | $24.0M | 3% |
